897657-96-4

Usage

Uses

Used in Pharmaceutical Industry:
(4-((PyriMidin-2-ylaMino)Methyl)phenyl)Methanol is used as a potential pharmaceutical candidate for various applications due to its unique structural features, including the presence of a pyrimidine ring which is a key component of many important bioactive compounds. Its potential uses may include the development of new drugs or therapies, but further research and study are required to fully understand its properties and potential applications.
Used in Chemical Research:
(4-((PyriMidin-2-ylaMino)Methyl)phenyl)Methanol may also be used in chemical research as a starting material or intermediate for the synthesis of more complex molecules with potential applications in various fields, such as materials science, pharmaceuticals, or agrochemicals. Its unique structural features make it an interesting compound for further exploration and study.

Upstream product

• 109-12-6 2-aminopyrimidine 
• 623-27-8 terephthalaldehyde, 

Downstream Products

• 1059145-68-4 (4-((benzylamino)methyl)-2-benzylidene-1-methylhydrazinyl)benzene 
• 1016884-98-2 C₁₂H₁₁N₃O₂ 
• 1002158-46-4 N-(4-((4-(pyrrolidin-1-yl)phenylamino)methyl)benzyl)pyrimidin-2-amine 
• 1002158-45-3 N-(4-((3-(pyrrolidin-1-yl)phenylamino)methyl)benzyl)pyrimidin-2-amine 
• 1002158-47-5 N-(4-((2-(pyrrolidin-1-yl)phenylamino)methyl)benzyl)pyrimidin-2-amine 
• 898195-93-2 MSX-221 
• 898195-88-5 MSX-219 

Relevant academic research and scientific papers

Anti-inflammatory hybrids of secondary amines and amide-sulfamide derivatives

The CXCR4/CXCL12 chemokine axis can chemotactically accumulate inflammatory cells to local tissues and regulate the release of inflammatory factors. Developing novel CXCR4 modulators may provide a desirable strategy to control the development of inflammation. A series of novel hybrids were designed by integrating the key pharmacophores of three CXCR4 modulators. The majority of compounds displayed potent CXCR4 binding affinity. Compound 7a exhibited 1000-fold greater affinity than AMD3100 and significantly inhibited invasion of CXCR4-positive tumor cells. Additionally, compound 7a blocked mice ear inflammation by 67% and suppressed the accumulation of inflammatory cells in an in vivo mouse ear edema evaluation. Western blot analyses revealed that 7a inhibited the CXCR4/CXCL12-mediated phosphorylation of Akt and p44 in a dose-dependent manner. Moreover, compound 7a had no observable cytotoxicity and displayed a favorable plasma stability in our preliminary pharmacokinetic study. These results confirmed that this is a feasible method to develop CXCR4 modulators for the regulation and reduction of inflammation.

Dipyrimidine amines: A novel class of chemokine receptor type 4 antagonists with high specificity

The C-X-C chemokine receptor type 4 (CXCR4)/stromal cell derived factor-1 (SDF-1 or CXCL12) interaction and the resulting cell signaling cascade play a key role in metastasis and inflammation. On the basis of the previously published CXCR4 antagonist 5 (WZ811), a series of novel nonpeptidic anti-CXCR4 small molecules have been designed and synthesized to improve potency. Following a structure-activity profile around 5, more advanced compounds in the N,N-(1, 4-phenylenebis(methylene)) dipyrimidin-2-amines series were discovered and shown to possess higher CXCR4 binding potential and specificity than 5. Compound 26 (508MCl) is the lead compound and exhibits subnanomolar potency in three in vitro assays including competitive binding, Matrigel invasion and Gαi cyclic adenosine monophosphate (cAMP) modulation signaling. Furthermore, compound 26 displays promising effects by interfering with CXCR4 function in three mouse models: paw inflammation, Matrigel plug angiogenesis, and uveal melanoma micrometastasis. These data demonstrate that dipyrimidine amines are unique CXCR4 antagonists with high potency and specificity.

CXCR4 ANTAGONISTS FOR THE TREATMENT OF HIV INFECTION

The invention provides compounds, pharmaceutical compositions and methods of use of certain compounds that are antagonists of the chemokine CXCR4 receptor, and in particular to inhibit viral entry of certain viruses. Certain compounds in particular can reduce entry of immunodeficiency virus (HIV) into a cell while not reducing the capacity of stem cells to proliferate, and therefore can be useful for long term treatment regimes. The compounds are useful in particular in the treatment or prevention of HIV infections.